OrbiMed Discloses 14.0% Stake in ADARx Pharmaceuticals After IPO

OrbiMed Advisors filed a Schedule 13D on Oct. 2 disclosing a 14.0% stake in ADARx Pharmaceuticals, built through $17-per-share IPO purchases and preferred stock conversions.